ReviewInternational urology and nephrology2026
Novel treatment strategies for C3 glomerulopathy: complement blockade.
Review in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complement Dysregulation in Kidney Diseases: Mechanisms, Biomarkers, and Emerging Targeted Therapies.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C3 glomerulopathy (C3G) is a rare kidney disease characterized by dysregulation of the alternative pathway of the complement system. Efficacy of the available treatment options is quite limited, and almost half of the patients progress to kidney failure within 10 years. Moreover, the disease is known to recur in 42-100% of patients after kidney transplantation. Conventional treatment approaches typically include a renin angiotensin system blocker and a combination of glucocorticoids and mycophenolic acid derivatives. Successful use of eculizumab has been reported in aggressive disease forms. Response to these strategies have been quite variable, and efficacy of eculizumab has not been shown in slowly progressive forms of C3G. New agents such as iptacopan and pegcetacoplan look very promising. Notably, use of both agents was recently approved by the United States Food and Drug Administration. Herein we review novel treatment strategies for patients suffering from C3G with a focus on agents targeting complement system.
Indexed as
Identifiers
41335387What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.